<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PRIMAQUINE PHOSPHATE - primaquine phosphate tablet </strong><br>PD-Rx Pharmaceuticals, Inc.<br></p></div>
<h1>PRIMAQUINE<br>PHOSPHATE<br>TABLETS, USP</h1>
<div class="Contents">
<div class="Warning">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">WARNING:</span> PHYSICIANS SHOULD COMPLETELY FAMILIARIZE THEMSELVES WITH THE COMPLETE CONTENTS OF THIS LEAFLET BEFORE PRESCRIBING PRIMAQUINE PHOSPHATE.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Primaquine phosphate is 8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline phosphate, a synthetic compound with potent antimalarial activity.  Each tablet contains 26.3 mg of Primaquine phosphate (equivalent to 15 mg of primaquine base).  The dosage is customarily expressed in terms of the base.</p>
<p><span class="Italics">Inactive Ingredients:</span>  Carnauba Wax, Hydroxypropyl Methylcellulose, Lactose, Magnesium Stearate, Microcrystalline Cellulose, Polyethylene Glycol 400, Polysorbate 80, Pregelatinized Starch, Red Ferric Oxide , Talc, Titanium Dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Primaquine phosphate is an 8-amino-quinoline compound which eliminates tissue (exoerythrocytic) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.  Thereby, it prevents the development of the blood (erythrocytic) forms of the parasite which are responsible for relapses in vivax <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>.  Primaquine phosphate is also active against gametocytes of <span class="Italics">Plasmodium falciparum</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, such as <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> and <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>.  The drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow.</p>
<p>Because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated.  Similarly, Primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Discontinue the use of Primaquine phosphate promptly if signs suggestive of <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> occur (darkening of the urine, marked <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> of hemoglobin or erythrocytic count).</p>
<p>Hemolytic reactions (moderate to severe) may occur in individuals with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency and in individuals with a family or personal history of <span class="product-label-link" type="condition" conceptid="4098744" conceptname="Favism">favism</span>.  Areas of high prevalence of G-6-PD deficiency are Africa, Southern Europe, Mediterranean region, Middle East, South-East Asia, and Oceania.  People from these regions have a greater tendency to develop <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> (due to a congenital deficiency of erythrocytic glucose-6-phosphate dehydrogenase) while receiving Primaquine and related drugs.</p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-5.1"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">Safe usage of this preparation in pregnancy has not been established.  Therefore, use of it during pregnancy should be avoided except when in the judgment of the physician the benefit outweighs the possible hazard.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Since <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> have been observed following administration of large doses of primaquine, the adult dosage of 1 tablet (= 15 mg base) daily for fourteen days should not be exceeded.  It is also advisable to make routine blood examinations (particularly blood cell counts and hemoglobin determinations) during therapy.</p>
<p>If primaquine phosphate is prescribed for (1) an individual who has shown a previous idiosyncrasy to primaquine phosphate (as manifested by <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, or <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>), (2) an individual with a family or personal history of <span class="product-label-link" type="condition" conceptid="4098744" conceptname="Favism">favism</span>, or (3) an individual with erythrocytic glucose-6-phosphate dehydrogenase (G-6-PD) deficiency or nicotinamide adenine dinucleotide (NADH) methemoglobin reductase deficiency, the person should be observed closely for tolerance.  The drug should be discontinued immediately if marked darkening of the urine or sudden decrease in hemoglobin concentration or leukocyte count occurs.</p>
<div class="Section" data-sectionCode="34082-8">
<a name="section-6.1"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of Primaquine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients.  In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Italics">Gastrointestinal</span>:  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>.</p>
<p><span class="Italics">Hematologic</span>:  <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> in glucose-6-phosphate dehydrogenase (G-6-PD) deficient individuals, and <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> in nicotinamide adenine dinucleotide (NADH) methemoglobin reductase deficient individuals.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Symptoms of overdosage of primaquine phosphate are similar to those seen after overdosage of pamaquine.  They include <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, burning <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, central nervous system and cardiovascular disturbances, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, moderate <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span> or <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.  The most striking symptoms are <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> and <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">acute hemolytic anemia</span> in sensitive persons.  Acute <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> occurs, but patients recover completely if the dosage is discontinued.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Primaquine phosphate is recommended only for the radical cure of vivax <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>, the prevention of relapse in vivax <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>, or following the termination of chloroquine phosphate suppressive therapy in an area where vivax <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> is endemic.  Patients suffering from an attack of vivax <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> or having parasitized red blood cells should receive a course of chloroquine phosphate, which quickly destroys the erythrocytic parasites and terminates the paroxysm.  Primaquine phosphate should be administered concurrently in order to eradicate the exoerythrocytic parasites in a dosage of 1 tablet (equivalent to 15 mg base) daily for 14 days.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Primaquine phosphate is supplied in tablets of 26.3 mg (= 15 mg base), bottles of 100.  (NDC 0024-1596-01)</p>
<p>Store at 25° C (77° F); excursions permitted to 15° – 30° C (59° – 86° F) [see USP Controlled Room Temperature]</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-11"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">Malariologists agree that <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> produced by Plasmodium vivax is the most difficult form to treat.  This is ascribed to the ability of the parasite to develop extremely resistant tissue forms which are not eradicated by ordinary antimalarial compounds.</p>
<p>Thus, persons with acute attacks of vivax <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>, provoked by the release of erythrocytic forms of the parasite, respond readily to therapy, particularly to Chloroquine phosphate. However, prior to the discovery of primaquine phosphate, no antimalarial drug was available that could be relied on to eliminate tissue (exoerythrocytic) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and to prevent relapses.  The various investigations made with primaquine in experimentally induced vivax <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> in human volunteers and in persons with naturally occurring <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> have demonstrated that the drug is a valuable adjunct to conventional therapy in this refractory form of the disease. </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Manufactured for<br>Sanofi-Synthelabo Inc.<br>New York, NY 10016<br>by Bayer Corporation<br>Myerstown, PA 17067</p>
<p>Made In USA</p>
<p>Revised November 2007</p>
<p>Copyright, Sanofi-Synthelabo Inc., 2007</p>
<p><span class="Bold">PSW-11E</span></p>
<p><span class="Bold">PD-Rx Labels</span></p>
<p><img alt="PD-Rx Labels" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=222f3d0a-7649-44ad-99b2-b2dc8c298e7b&amp;name=43063225.jpg"></p>
</div>
<div class="Section" data-sectionCode="48780-1">
<a name="section-13"></a><p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRIMAQUINE PHOSPHATE 		
					</strong><br><span class="contentTableReg">primaquine phosphate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43063-225(NDC:0024-1596)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PRIMAQUINE PHOSPHATE</strong> (PRIMAQUINE) </td>
<td class="formItem">PRIMAQUINE PHOSPHATE</td>
<td class="formItem">26.3 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink (light buff colored) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">W;P97</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:43063-225-14</td>
<td class="formItem">14  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:43063-225-28</td>
<td class="formItem">28  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA008316</td>
<td class="formItem">01/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>PD-Rx Pharmaceuticals, Inc.
							(156893695)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PD-Rx Pharmaceuticals, Inc. (156893695)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PD-Rx Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">156893695</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2008<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f94091aa-1ed9-463a-92a5-71136ae0af11</div>
<div>Set id: 222f3d0a-7649-44ad-99b2-b2dc8c298e7b</div>
<div>Version: 1</div>
<div>Effective Time: 20081016</div>
</div>
</div> <div class="DistributorName">PD-Rx Pharmaceuticals, Inc.</div></p>
</body></html>
